Angiopoietin-2 as a biomarker for metabolic syndrome and disease activity in rheumatoid arthritis patients

详细信息    查看全文

• 作者：Abdel Hamed A. Hares Ghazaly^a ; Khalid M.A. El-Moez^a ; Mohamed S. El Shorbagy^b ; Eslam M. El-Nahrery^c ; ^{elnahreryeslam2@yahoo.com" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Metabolic syndrome ; Rheumatoid arthritis ; Angiopoietin-2 ; Disease activity score (DAS-28)
• 刊名：The Egyptian Rheumatologist
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：38
• 期：1
• 页码：9-13
• 全文大小：584 K

文摘

The incidence of metabolic syndrome (MetS) increases in rheumatoid arthritis (RA) patients which increases the risk of cardiovascular disease (CVD). Angiopoietin-2 levels increase in RA and were reported to predict CVD.

Aim of the work

To assess the level of angiopoietin-2 in RA patients and study its relation to disease activity and its role in those with MetS.

Patients and methods

The study included 80 RA patients (67 females and 13 males) and 20 healthy age and sex matched controls. The patients were divided into Group 1 (n = 40) with MetS and Group 2 (n = 40) without. Data were collected throughout history, basic clinical examination and investigation. Disease activity score (DAS-28) was assessed in all patients. Enzyme linked immunosorbent assay was used for the estimation of angiopoietin-2.

Results

The age and disease duration of those with MetS (40.7 ± 7.23 years and 9.63 ± 6.73 years respectively) and those without (38.6 ± 9.2 and 8.65 ± 5.52 years respectively) were comparable (p = 0.26 and p = 0.48 respectively). The disease activity (DAS-28) was also similar in both groups (5.12 ± 0.77 and 5.01 ± 0.96 respectively; p = 0.56). There was a significant increase in the angiopoietin-2 levels in RA patients with MetS (5.31 ± 0.56 ng/ml) than those without (4.93 ± 0.44 ng/ml) (p < 0.001). The levels were significantly higher than those of the control (4.44 ± 0.29 ng/ml) (p < 0.001). The angiopoietin-2 level significantly correlated with the DAS-28 (r = 0.23, p = 0.045), systolic (r = 0.36, p = 0.001) and diastolic blood pressure (r = 0.35, p = 0.001), fasting blood sugar (r = 0.29, p = 0.009) and triglycerides (r = 0.24, p = 0.03).

Conclusions

Angiopoietin-2 can be used as a biomarker of MetS and disease activity in RA patients. This could point to those RA patients at risk of developing CVDs.